The preventive-care clinic adds hormone testing, menopause care and longitudinal risk tracking built specifically around female biology.
Ask most women what their annual physical covers, and you’ll get some version of the same answer: not much, and definitely not menopause. It’s a gap Biograph – the preventive health and diagnostics clinic co-founded by Peter Attia that made its name promising to “redefine healthy aging” through five-to-six-hour, data-dense visits – is now trying to close with a dedicated Women’s Health Program [1].
The program folds a female-specific health history, personalized hormone testing, a broader risk assessment, menopause care and tailored nutrition and exercise guidance into Biograph’s existing physician-led model, available to members on both its Core and Black tiers.
Biograph is leaning on a statistic that’s uncomfortable by design. According to a 2024 report the company cites, US women had a life expectancy of 80 years in 2022, at least two years shorter than women in each of 13 comparator countries, and the highest rate of avoidable mortality among all of them. In a country that spends more on healthcare than almost anywhere else, that’s not a small gap. It suggests the system isn’t just imperfect, but is structurally missing something for half the population.
Menopause care is a good example of what’s being missed. Biograph cites a study of nearly 5,000 midlife US women in which 34% reported moderate to severe menopause symptoms, yet roughly 87% of that group never sought medical care for it. Part of the problem, the company argues, is recognition: symptoms like mood changes, brain fog, disrupted sleep, bone loss and creeping abdominal fat often don’t get connected back to menopause at all, even by the people experiencing them.
What the program actually adds
The new offering has three working parts. A female-specific health history captures reproductive and menstrual background, pregnancy history and family risk factors that standard intake forms tend to skip. Hormone testing and risk assessment are tailored to each woman’s symptoms and life stage, then read alongside imaging and lab work to build a picture of cardiovascular, metabolic, bone, cognitive and cancer risk. And ongoing lifestyle guidance – nutrition, exercise, hormone health – is meant to evolve as a woman moves through different life stages rather than resetting at every visit.
For members who are clinically eligible, Biograph can also add menopausal hormone therapy through its prescription management service, with physicians overseeing dosing and monitoring over time.
“Women’s health is deeply interconnected, but the way we deliver care often isn’t,” said Dr Yihan Chen, a physician at Biograph. “A woman’s menstrual and reproductive history, her hormonal shifts through the menopause transition, her cardiovascular, metabolic, and bone health – these aren’t separate stories. They intersect in complex ways to shape her long-term health.”
Chen explained that their Women’s Health Program integrates these components by combining advanced diagnostics with personalized clinical guidance. She noted that this approach empowers women to gain a complete understanding of their well-being and take proactive measures to enhance both their current daily health and their long-term medical outlook.
The results Biograph is pointing to
The company says 71% of female Black-tier members have reversed insulin resistance and reduced their overall lifetime cardiovascular risk – a driver of disease that, left undetected, tends to build quietly for years [1]. Among returning female members generally, 96% report measurable progress toward their health goals.
Biograph has always framed its mission around healthspan as much as lifespan, the idea that how well you live matters as much as how long. A women’s-specific program is a fairly direct extension of that logic: menopause isn’t a side issue in aging biology; it’s one of its more dramatic inflection points, touching bone density, metabolic health, cardiovascular risk and cognition more or less simultaneously. Treating it as background noise, rather than a signal worth tracking closely, has arguably cost the field years of useful data on how women actually age. Whether a membership-based clinic model can scale that insight beyond a wealthy few is a separate question, but as a statement of where preventive medicine still has ground to make up, it’s a pointed one.
